Calidi Biotherapeutics, Inc. - Schedule 13D Filing

Ognian Anguelov Gavrilov, a significant shareholder in Calidi Biotherapeutics, Inc., has reported a disposition of shares, reducing his beneficial ownership to approximately 0.3% of the outstanding shares. This transaction, which occurred on March 31, 2026, involved the disposal of 20,000 shares. Gavrilov & Brooks, where Gavrilov serves as Managing Partner, is located at 2315 Capitol Avenue, Sacramento, CA 95816. The filing indicates that Gavrilov currently has no plans or proposals that would lead to any significant actions concerning the issuer, as detailed in Item 4 of Schedule 13D. However, he reserves the right to acquire or dispose of additional securities in the future, based on market conditions and other factors. The filing also confirms that Gavrilov has not been convicted of any relevant offenses.